# EDGAR Filing Document

**Accession Number:** 0001824293
**File Stem:** 0001628280-25-056216
**Filing Date:** 2025-12
**Character Count:** 3089
**Document Hash:** 6df0a0c71b40070177da61898f047a7a
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001628280-25-056216.hdr.sgml**: 20260515

**ACCESSION NUMBER**: 0001628280-25-056216

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20251209

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GRI Bio, Inc.
- **CENTRAL INDEX KEY:** 0001824293
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 824369909
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
- **BUSINESS PHONE:** (619) 400-1171

**MAIL ADDRESS:**
- **STREET 1:** 2223 AVENIDA DE LA PLAYA
- **STREET 2:** SUITE 208
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GRI BIO, Inc.
- **DATE OF NAME CHANGE:** 20230424

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Vallon Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20200910

**GRI BIO, INC.**

**2223 AVENIDA DE LA PLAYA, SUITE 208**

**LA JOLLA, CA 92037**

---

| | |
|:---|:---|
| ***VIA EDGAR*** | ***VIA EDGAR*** |
| December 9, 2025 | December 9, 2025 |
| U.S. Securities and Exchange Commission | U.S. Securities and Exchange Commission |
| Division of Corporation Finance | Division of Corporation Finance |
| Office of Life Sciences | Office of Life Sciences |
| 100 F Street, N.E. | 100 F Street, N.E. |
| Washington, D.C. 20549 | Washington, D.C. 20549 |
| Attn: Doris Stacey Gama | Attn: Doris Stacey Gama |
| **Re:** | **GRI Bio, Inc.** |
|  | **Registration Statement on Form S-1, as amended (File No. 333-291999)** |
|  | **Request for Acceleration of Effective Date** |

---

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, GRI Bio, Inc. (the "**Company**") hereby requests that the Securities and Exchange Commission (the "**Commission**") accelerate the effective date of the above-referenced Registration Statement on Form S-1 (the "**Registration Statement**") so that the Registration Statement will be declared effective as of 5:15 p.m. Eastern Time, on December 10, 2025, or as soon as practicable thereafter. The Company hereby authorizes Melanie Ruthrauff Levy, an attorney at the Company's outside legal counsel, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., to orally modify or withdraw this request for acceleration.

Once the Registration Statement has been declared effective, please orally confirm that event with Ms. Levy at (858) 314-1873.

Thank you for your assistance in this matter.

---

| | | |
|:---|:---|:---|
| | | Very truly yours, |
| | | GRI BIO, INC. |
| | | */s/ W. Marc Hertz, Ph.D.* |
| | | W. Marc Hertz, Ph.D. |
| | | Chief Executive Officer |
| cc: | *<u>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</u>* | *<u>Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C.</u>* |
| | Adam Lenain, Esq. | |
| | Melanie Ruthrauff Levy, Esq. | |

---

<br>